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Giant cell tumor of bone: current review of morphological, clinical, radiological, and 
therapeutic characteristics
Kemiğin dev hücreli tümörü: Morfolojik, klinik, radyolojik ve tedavi özelliklerinin gözden 
geçirilmesi
Georgi P. Georgiev1, Svetoslav Slavchev1, Iva N. Dimitrova2, Boycho Landzhov3
ÖZET
Kemiğin dev hücreli tümörü erişkinlerdeki tüm primer ke-
mik  tümörlerinin  %5’ini  oluşturur  ve  kemik  tümörlerinin 
en güç ve yoğun araştırılanıdır. Bu durum büyük ölçüde 
tekrarları öngörmeye izin veren tek tip klinik, radyografik, 
histolojik ve morfolojik özelliklerinin olmayışı nedeniyledir. 
Dünya Sağlık Örgütü tarafından agresif potansiyeli olan 
malign bir lezyon olarak sınıflandırılan kemiğin dev hücreli 
tümörü akciğere metastaz yapar ve malign dejenerasyon 
veya çok merkezli lokalizasyon gösterir. Tümör genellikle 
uzun kemiklerde oluşur, ancak alışılmadık lokalizasyon-
larda da olabilir. Yaygın semptomu tümör bölgesindeki ar-
tan ağrıdır. Standart tedavi küretajdan geniş rezeksiyona 
kadar değişir ve değişik onkolojik ve fonksiyonel sonuçlar 
doğurur.  Tümör  evresine  bakılmaksızın,  cerrahiyi  takip 
eden ilk 2-3 yılda tekrarlama riski yüksektir. Bu yazıda bu 
patolojik teşekkülün morfolojik, klinik, radyolojik ve tedavi 
özellikleri ile ayırıcı tanısı tartışılmıştır.
Anahtar kelimeler: Kemiğin dev hücreli tümörü, tanı, te-
davi, derleme
ABSTRACT
Giant cell tumor of bone accounts for about 5% of all pri-
mary bone tumors in adults and is still one of the most 
obscure and intensively examined tumors of bone. This 
largely  results  from  the  lack  of  uniform  clinical,  radio-
graphic, histological or morphological aspects that allow 
prediction of recurrence. Classified by the World Health 
Organization as “an aggressive, potentially malignant le-
sion”, the giant cell tumor of bone could give lung me-
tastases, could undergo malignant degeneration or could 
have multicentric localization. It usually develops in long 
bones but can also occur in unusual locations. The com-
mon presenting symptom is increasing pain at the tumor 
site. Standard treatment ranges from curettage to wide 
resection, with reports of varying oncological and func-
tional results. The recurrence rate is high during the first 
2-3 years after surgery regardless of pre-operative tumor 
stage. Herein, we discuss the morphological, clinical, ra-
diological, and therapeutic characteristics of this patho-
logic entity as well as its differential diagnosis. J Clin Exp 
Invest 2014; 5 (3): 475-485
Key words: Giant cell tumor of bone, diagnosis, treat-
ment, review.
INTRODUCTION
Giant cell tumor of bone (GCTB) is usually a be-
nign bone tumor with a high rate of recurrence and 
possibility  of  “benign”  pulmonary  metastases  or 
transformation in a malignant blastoma [1-4]. Nu-
merous terms including myeloid sarcoma, tumor of 
myeloplaxus, osteoblastoclastoma, and osteoclas-
toma have been used to depict this tumor [5,6]. It 
accounts for about 5% of all primary bone tumors 
in adults and predominantly occurs in the third and 
fourth decade of life with a slight predilection for fe-
males [2,7,8]. GCTB is described as a locally inva-
sive tumor that arises close to a joint in a mature 
bone  [2,9].  It  usually  affects  the  meta-epiphyseal 
region of long bones, preferably the bones around 
the knee joint, the distal radius, and the proximal 
humerus [1-4,10]. The definitive treatment of GCTB 
varies from intralesional curettage with or without 
different adjuvants followed by bone grafting and/or 
bone cement packing to wide resection which could 
compromise limb function [1-4,10].Georgiev G.P. et al. Giant cell tumor of bone 476
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In  this  report,  we  review  the  pathologic  fea-
tures,  clinical  manifestations,  radiological  appear-
ance, different forms of GCTB, and the treatment 
of this lesion.
PATHOLOGICAL FEATURES
Gross findings
GCTB has a variable gross appearance. It usually 
presents as a large lesion eccentrically located in 
the epiphysis, extending toward the articular car-
tilage and toward the metaphysis [7,11]. GCTB is 
usually meaty, soft, purple-red to brown, and may 
be uniform or variegated in gross appearance, with 
small, squishy yellow necrotic foci or extensive ar-
eas of cystic change [7,11]. Soft-tissue extensions 
are not uncommon and appear as a well-defined 
mass with peripheral calcification [7].
Microscopic findings
In the current literature, GCTB is described as a 
predominantly osteoclastogenic stromal cell tumor 
of mesenchymal origin [12]. It is composed of large 
multinucleated osteoclast-like giant cells distributed 
amongst  mononuclear  spindle-like  stromal  cells 
and other monocytes (Figure 1) [12-14].
Figure 1. Photomicrograph demonstrating multinucleated 
giant cells, spindle cells and mononuclear monocyte cells.
The multinucleated giant cells which mimic os-
teoclasts are principally responsible for the exten-
sive bone resorption that is characteristic of GCTB 
[14]. Their size is about 60 μm and they contain 
from 20-30 to 100 or more nuclei located central-
ly. They react positively with tartrate-resistant acid 
phosphatase,  cathepsin  K,  carbonic  anhydrase 
II,  α-naphthyl  esterase  enzymes,  different  matrix 
metalloproteinases,  and  with  a  number  of  recep-
tors  such  as  receptor  activator  of  nuclear  factor 
kappa-B (RANK), calcitonin receptor, αvβ3 integrin, 
which are characteristic of osteoclasts [14-17]. On 
electron microscopy these cells are described as 
multi-nucleated, osteoclast-like giant cells [18-20]. 
In the past, particularly in British literature GCTB 
was called osteoclastoma due to the abundance of 
these cells.
The spindle-like stromal cells are the main neo-
plastic component of GCTB and have been shown 
to  express  and  secrete  a  variety  of  chemotactic 
factors to enlist pathologic components [12,14,21]. 
They play an important role in the formation of gi-
ant multinucleated cells [7,8,14,17]. The spindle-like 
stromal cells have great potential to proliferate, pro-
duce collagen type-I and II, alkaline phosphatase, 
matrix metalloproteinases and they have receptors 
for parathyroid hormone. Spindle-like stromal cells 
secrete macrophage colony stimulating factor (M-
CSF), interferon gamma (IFN-gamma), and tumor 
necrosis factor alpha (TNF-α), which have chemo-
tactic, differentiation-inducing and activating effects 
on mononuclear monocyte cells and are essential 
for  the  differentiation  of  osteoclasts  [8,13,22,23]. 
Spindle-like stromal cells also have receptor activa-
tor of nuclear factor kappa-B ligand (RANKL) which 
plays an important role in osteoclastogenesis. At the 
ultrastructural  level,  spindle-shaped  mononuclear 
cells resemble fibroblasts [18-20].
The monocyte cells are considered to be ei-
ther  reactive  macrophages  or  osteoclast  precur-
sors [12,14]. They express monocyte-macrophage 
markers  such  as  tartrate-sensitive  acid  phospha-
tase, α-naphthyl esterase, and react with monoclo-
nal antibodies to CD11a, CD13 , CD18, and CD68, 
suggesting that these cells have monocyte-macro-
phage  origin  [7,8,17,24].  Khurana  and  McCarthy 
[17] reported that the giant multinucleated cells are 
formed by the fusion of these cells, but not from the 
spindle-like  stromal  cells.  Polygonal  mononuclear 
cells are similar to macrophages, in regard to their 
ultrastructural characteristics [18-20].
Many authors have attempted to grade these 
tumors  histologically  but  no  grading  system  has 
proved to be of prognostic significance in terms of 
recurrence rates or occurrence of metastases [25-
27]. Pulmonary metastases in GCTB histologically 
do not differ from the bone lesion [17].
The  pathologic  differential  diagnosis  of  the 
GCTB  includes  aneurysmal  bone  cyst,  benign  fi-
brous  histiocytoma,  foreign  body  reaction,  chon-
droblastoma,  giant-cell-rich  osteosarcoma,  osteo-Georgiev G.P. et al. Giant cell tumor of bone 477
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blastoma, and brown tumor of hyperparathyroidism 
[7,28].
Clinical manifestations
The main clinical symptoms are non-specific and 
include pain of variable severity, local swelling, ten-
derness of the affected area, and limited range of 
motion of the adjacent joint [1,7,8,17,28]. The du-
ration of symptoms varies from two to six months. 
Rarely, a pathologic fracture may be the first symp-
tom [1,7,8,17,28]. Neurologic symptoms may be as-
sociated with spinal lesions [7].
RADIOLOGICAL APPEARANCE
The most important feature that often strongly sug-
gests the diagnosis of GCTB is the location of the le-
sion [29,30]. Commonly, this tumor affects the distal 
femur (27%), followed by the proximal tibia (21%) 
[1-4,10]. Other locations reported in the literature 
are the distal radius (8%), the sacrum (6%), and 
the proximal humerus (5%) [31-33]. Rarely, GCTB 
could involve the proximal femur, the vertebra, the 
distal tibia, the proximal fibula, the hand, and the 
foot [34-36]. Extremely rarely, this tumor could af-
fect the greater trochanter [30].
On radiographs, GCTB typically presents as a 
lucent lesion without matrix calcifications growing 
often, but not exclusively, eccentrically in the epime-
taphyseal region of the bone, generally in a skeletal-
ly mature patient [1,2,7,8,10]. In indolent and static 
tumors, the margins of the lesion are well-defined, 
without  sclerosis  changes.  In  aggressive  cases, 
margins are poorly demarcated and the cortex may 
be  thinned,  distended,  or  destroyed  with  soft  tis-
sue extension, but a periosteal reaction is generally 
lacking [7,8,10]. Marginal sclerosis may be present 
in old or inactive lesions, and peripheral ossification 
around a soft tissue recurrence or a lung metasta-
sis [28]. Complete or incomplete pathologic fracture 
after bony destruction could also be detected [37].
Campanacci et al. [38] classified GCTB in three 
grades: grade 1 - a static form with minimal involve-
ment of the cortex, grade 2 in which the cortex is 
thinned and expanded, and grade 3 in which the 
lesion penetrates the cortex and has a soft tissue 
component. 
The radiographic differential diagnosis of GCTB 
includes juvenile solitary or aneurysmal bone cysts, 
chondroblastoma,  chondromyxoid  fibroma,  giant-
cell  reparative  granuloma,  nonossifying  fibroma, 
eosinophylic granuloma, high-grade central osteo-
sarcoma [7,8].
As with any suspicious bone lesion, full staging 
with MRI and CT should be undertaken [7,39]. CT 
is useful in the evaluation of the cortical bone and 
could clearly present thinning of the cortex, patho-
logic fracture, periosteal reaction, and absence of 
matrix mineralization [8,37]. In cases of cortical de-
struction and soft-tissue tumor extension, MRI is su-
perior to CT in delineation of GCTB [7,8]. The tumor 
appears with a nonhomogenous signal on MRI: low 
in T1-weighted images and high in T2-weighted im-
ages [28]. Moreover, MRI could also present fluid-
fluid  levels  typical  for  the  aneurysmal  bone  cyst, 
thus helping in distinguishing the aneurysmal bone 
cyst from the GCTB [7]. Bone scintigraphy could 
also be used for the evaluation of giant cell tumor of 
bone [40, 41]. However this imaging modality is not 
specific and it is only helpful in evaluating patients 
with multicentric or metastatic GCTB [42].
Malignant GCTB
Malignant GCTB is rare and is divided into primary 
and secondary [7,43]. Primary malignant GCTB is 
the rarest (about 1-3 % of all cases of GCTB) and 
has cells characteristic of a sarcomatous process 
located in areas of typical benign GCTB [7,32,43]. 
Secondary malignant GCTB is present in 5-10 % of 
cases and is described as a metachronous highly 
differentiated sarcoma that is superimposed on a 
primary histologically benign GCTB after surgery or 
radiotherapy [7,9,32,43]. The clinical features of pri-
mary and secondary malignant GCTBs are similar 
to those of a benign lesion; the primary is virtually 
indistinguishable by radiography while the second-
ary has a much more malignant radiographic ap-
pearance but sometimes it too is indistinguishable 
from a benign lesion [43]. It is believed that sec-
ondary malignant GCTB has two types with differ-
ent  etiology  -  post-surgical  and  radiation-induced 
although they cannot be distinguished from each 
other either radiographically  or histologically  [43]. 
Primary  malignant  GCTB  must  be  distinguished 
from an osteosarcoma rich in giant cells. Differen-
tiating these two tumors is sometimes difficult, with 
limited application in clinical practice. More impor-
tantly, they are both difficult to be differentiated from 
a benign GCTB. The diagnosis of primary malignant 
GCTB is difficult, because it contains benign areas 
and therefore biopsies may not detect malignancy 
of the tumor in the beginning [43-45]. Sakkers et 
al. [45] propose a theory regarding the malignant 
transformation  of  a  GCTB  treated  with  curettage 
and autograft and they assume that reparative pro-
liferative changes that occur in the bone graft could 
serve as a nidus for the formation of a malignant Georgiev G.P. et al. Giant cell tumor of bone 478
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tumor. In the literature there are cases in which sar-
comatous degeneration happened even 25 years 
after primary surgery of GCTB [46].
Benign metastasizing GCTB
Benign metastatic GCTB represents 1% to 3% of all 
GCTB and 6% of the recurrences [47-49]. Its bio-
logical behavior is unpredictable [50,51]. The most 
frequent benign GCTB metastases are in the lung 
but although extremely rare, metastases have been 
described  in  lymph  nodes  and  even  in  the  scalp 
[50]. In those cases, the metastases were histologi-
cally identical to those of the bone lesion [47]. “Be-
nign” lung metastases (single or multiple) were di-
vided into three groups: (1) fixed or ones that show 
spontaneous regression, (2) with slow growth, and 
(3) with rapid growth [51]. Disappearance of metas-
tases after biopsy has also been reported in the lit-
erature [52]. Some authors believe that such metas-
tases are due to secondary emboli in a peripheral 
vascular lesion and that they should be accepted as 
implantable in the lung but not as true metastases 
[53,54]. Others, however, have found no relation-
ship between the incidence of tumor emboli in these 
vessels and pulmonary metastases [55,56]. Rock et 
al. [57], Maloney et al. [56], Prosser et al. [48] have 
suggested that metastases occur more frequently in 
cases of aggressive lesions with soft tissue compo-
nents and after of one or more recurrences. Tubbs 
et al. [58] noted that lesions of the distal radius more 
frequently produce lung metastases.
Any  authors  indicate  elevated  MMPs,  higher 
expression of p53 protein and over expressed C-
myc oncogene in metastatic GCTB [59,60]. Lung 
metastases often occur two or three years after the 
treatment of the primary lesions [47,61]. Sometimes 
they are present at the time of detection of the bone 
lesion. Therefore,  it  is  necessary  to  obtain  chest 
radiographs before primary surgery and during the 
follow-up. Lung metastases could show peripheral 
ossification on radiographs but in general they have 
nonspecific  imaging  characteristics  [7]. The  pres-
ence of lung metastases in GCTB does not neces-
sarily mean a poor prognosis [53,56].
Мulticentric GCTB
The multicentric form of GCTB represents about 1 
% of all cases (Figure 2a-d) [62-64]. There are dif-
ferent theories about the mechanism of GCTB that 
affects multiple locations: contiguous spread, iatro-
genic dissemination, benign metastasis, malignant 
transformation, and de novo formation [65]. Lesions 
may occur simultaneously or with an interval of more 
than a decade [63]. Hoch et al. [63] present the most 
frequent localizations: around the knee, followed by 
the proximal humerus and the distal radius. Dhillon 
and Prasad [65] reported that multicentric GCTB of-
ten affects bones of the hand and the foot, and it is 
more often located in the meta-diaphysis of the long 
bone than solitary lesions and that it has a higher in-
cidence in females and in subjects with incomplete 
bone growth. Multicentric GCTB does not differ from 
the solitary tumor regarding its radiological, histo-
logical, and therapeutic aspects. Radiological and 
histological characteristics, as well as in the treat-
ment of multicentric GCTB, are not different from 
that of the solitary lesions [2,66].
Figure 2. A case of a multicentric GCTB: a) preoperative antero-posterior radiograph of a diaphyseal GCTB of hu-
merus; b) AP radiograph after extended intralesional curettage and cementation reinforced with Küntscher nails; c) 
preoperative AP radiograph of a diaphyseal GCTB of tibia; d) AP radiograph after segmental resection and structural 
allogenic bone grafting.Georgiev G.P. et al. Giant cell tumor of bone 479
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TREATMENT
GCTB is one of the most discussed bone tumors 
today. This result from the fact that there are no 
single  clinical,  radiographic,  histological  aspects 
that provides a reliable predictive value in terms of 
recurrence. Wang et al. [67] believes that the defini-
tion of the ideal method of treatment of GCTB is too 
subjective and varies depending on the experience 
and  expertise  of  the  surgeon. The  recommenda-
tions regarding the treatment of GCTB were based 
on retrospective analysis of the non-randomized se-
ries of one or many centers. Most surgeons believe 
that the best treatment should provide good local 
control and preserve limb function, curettage being 
their method of choice.
CURETTAGE
The main classifications determining surgical treat-
ment are those of Enneking [68] and Campanacci 
et al. [38]. Although their prognostic significance is 
still under discussion, they are used consistently for 
preoperative planning [69-71]. Many authors do not 
regard these staging systems as predictive of the 
prognosis  [8,10,25,26,47,69].  However,  other  au-
thors describe an increased incidence of recurrence 
in third grade lesions [48,72-74].
In the literature various adjuvants have been 
used in the treatment of GCTB after curettage but 
no prospective randomized trials compare their ef-
fects. The adjuvants have been used after curettage 
because of their physical (cryotherapy, hyperther-
mia,  high-pressure  pulsatile  lavage,  high-speed 
dental burr, argon beam coagulation) or chemical 
(phenol, hydrogen peroxide, alcohol, methotrexate) 
effects [2,7,8,25,26,75,76]. Fracture, skin necrosis, 
nerve injury, and osteoarthritis have been reported 
as  potential  complications  from  cryotherapy  and 
phenol application [77].
The  most  widely  used  adjuvant  in  the  treat-
ment of GCTB is polymethylmetacriylate (PMMA) 
bone  cement  (Figure  2b)  [2,49,70,78,79].  Pack-
ing the defect with bone cement after curettage is 
advantageous in that it is cheap, allows immediate 
weight-bearing,  and  provides  optimal  radiological 
conditions to easily identify local recurrences by ra-
diography, CT, and MRI [2,8,49,70,76,78,79]. The 
other option of filling the cavity after curettage is 
bone grafting. There are no prospective randomized 
trials to demonstrate the effect of different methods 
of filling the cavity [69]. The advantages of bone 
grafting are restoration of normal biomechanics to 
the joint surface, decreasing the risk of osteoarthri-
tis, and restoration of bone stock (Figure 3a-d). The 
disadvantages of this method are the need of pro-
longed protection of the limb because of the risk of 
pathological fracture and the difficulty in distinguish-
ing recurrent GCTB from graft resorption.
Figure 3. Preoperative AP radiograph (a) and CT (b) of a meta-epiphyseal GCTB of proximal tibia; c, d) AP and lateral 
radiographs after extended intralesional curettage and allografting with freeze-dried cancellous bone and cortical struts.
Although  many  authors  believe  that  the  use 
of an adjuvant lowers the risk of recurrence, other 
authors suggest that aggressive curettage through 
a large window that allows inspection of the entire 
lesion is the single most important factor in treat-
ment  outcome  [48,75,80,81].  Algawahmed  et  al. 
[81] based on a meta-analysis of six retrospective 
studies have found no evidence in favor of the use 
of an adjuvant after curettage and high-speed burr-
ing in terms of local control of the disease.
According  to  some  authors,  a  soft  tissue 
component is not a contraindication for curettage Georgiev G.P. et al. Giant cell tumor of bone 480
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[2,70,78,79]. The advantage is avoiding a complex 
skeletal reconstruction at an early age, and the dis-
advantage is a higher risk of recurrence. Consider-
ing the benign nature of the lesion, the young age 
of the patients, and the possible complications, it is 
believed that resection as primary treatment should 
be avoided [82,83]. Resection is used in patients 
with significant soft tissue components and lesions 
with more aggressive localization.
EN-BLOC RESECTION
In  cases  of  excessive  cortical  destruction,  soft-
tissue tumor extension (stage 3) with a large bone 
defect and destroyed joint surface, en-bloc resec-
tion is indicated. However, the main problem in the 
choice of surgical treatment of third stage lesions 
is that there is no precise definition of “large” and 
“excessive” destruction of the cortex and soft tissue 
component [2,67,69-71].
After resection, reconstruction with bone graft-
ing or a metal prosthesis is necessary (Figure 2 c,d; 
Figure 4a-d). Autografts (nonvascularised or vascu-
larised fibula) have been used in aggressive lesions 
at the distal radius and distal tibia with consequent 
arthrodesis or arthroplasty of these joints [7,8,84-
87]. Resected portions of the distal femur or proxi-
mal tibia have been replaced by osteoarticular al-
lografts or tumor prostheses [88,89]. In cases when 
GCTB is localized in the proximal fibula, distal ulna, 
and the wing of the ilium reconstruction after en-
bloc resection is not necessary [8]. Location in the 
vertebral column, the sacrum or the periacetabular 
region of the pelvis impedes the surgical procedure 
[8,90]. Preoperative transcatheter arterial emboliza-
tion could reduce blood loss during surgery [8].
Figure 4. Preoperative AP radiograph (a) and MRI slices (b, c) of a GCTB of proximal humerus; d) AP view after wide 
resection and replacement of the proximal humerus with a custom-made prosthesis.
Treatment after pathological fracture 
It is believed that larger lesions with more aggres-
sive course may cause pathological fracture [67]. In 
the literature, 20-30% of GCTBs had a pathologic 
fracture at presentation [49,91].
Deheshi et al. [91] indicate that there is no dif-
ference in terms of recurrence after curettage in pa-
tients with or without a pathological fracture. Drein-
höfer et al. [92] also believe that pathological fracture 
is not a contraindication for curettage and PMMA. In 
contrast Dreinhöfer et al. [92] and Lewis et al. [93] 
considered pathological fractures to indicate poten-
tially more aggressive lesions where more aggres-
sive treatment was needed as those cases showed 
a higher rate of recurrence and worse functional re-
sults. Turcotte et al. [27] in a Canadian multicenter 
study involving 186 patients present that displaced 
fracture is a prognostic factor for local recurrence. 
In the literature, however, there is little data regard-
ing the incidence of local recurrence in patients with 
and without pathological fracture [48,49,69].
Treatment of recurrences
In the literature there is no consensus on treatment 
of recurrences. An early diagnosis of recurrence al-
lows repeated curettage and avoids resection and 
subsequent  reconstruction  [32,  49,94,95].  Some 
authors [48,96] recommend wide resection followed 
by reconstruction with individual prostheses. Others 
recommend repeated curettage and PMMA [2,82]. 
Balke et al. [97] studied the outcome of treatment of 
recurrences of GCTB and reported on implantation 
of 14 endoprostheses in 67 patients (21 %), which 
is too high a percentage for a benign lesion.Georgiev G.P. et al. Giant cell tumor of bone 481
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Treatment of multicentric lesions, malignant 
GCTB, pulmonary metastases
With respect to treatment of multicentric lesions, it 
should be noted that the indications for the type of 
surgery are the same as in the case of a solitary 
lesion [2,66].
The treatment of malignant GCTB includes a 
resection according to oncological criteria and com-
bined with chemotherapy [8]. However, the progno-
sis of this tumor is not good: five years survival in 
50% of cases [8,98].
Complete excision of the pulmonary metasta-
ses in most cases leads to good results, but 16% 
to  25%  of  reported  cases  have  been  described 
as  deathly  [25,26,51,53,56,99].  Radiation  therapy 
and chemotherapy have only a limited application 
[52,57].
RECURRENCE
The recurrences rate of GCTB most often ranges 
about  12-65  %  after  curettage  and  osteoplasty 
[2,10,27,48,75] 12-27 % after curettage of an ad-
ditional adjuvant, such as high-speed burring, hy-
drogen  peroxide,  phenol,  PMMA  [2,49,78]  and 
0-12% after en-bloc resection [2,69]. Errani et al. 
[69] believe that the exact frequency of recurrences 
after  curettage  is  very  difficult  to  be  established. 
Some authors present series without recurrences, 
[80,100] while in others it varies from 6-8% [101] 
to 30-75% [96]. The reoccurrence rate is 25-35 % 
in older series and 10-20 % in recent series [69]. 
Despite the lowest rate of recurrence observed in 
patients after resection, it is not recommended for 
primary treatment because it leads to significant im-
pairment of limb function [2,10,49,69,78].
PROGNOSTIC FACTORS
Kivioja et al. [49] determined the age of the patient 
and the surgical margins as prognostic factors of 
recurrence. Younger patients have a slightly higher 
risk of recurrence; it decreases every year by about 
2 percent. Klenke et al. [70] analyzed the results 
in 118 patients with GCTB and found that age at 
diagnosis predicted the probability of recurrence re-
gardless of the stage of the lesion and the aggres-
siveness of the approach chosen. The higher risk of 
recurrence in young patients is probably related to 
more intensive bone turnover [73]. This hypothesis 
is supported by studies showing that the inhibition 
of bone turnover with bisphosphonates reduces the 
risk of recurrence [102]. However, many authors be-
lieve that the recurrence rate does not correlate with 
age [2,10,27,69,71,73,74].
The prognostic significance of cortical destruc-
tion and the presence of a soft tissue component 
is  still  debatable  [2,69,70,78].  Prosser  et  al.  [48] 
believes that the risk of recurrence correlates with 
the degree of cortical destruction; it is only 7% in 
patients  with  endosteal  tumors  and  29%  in  pa-
tients  with  evidence  of  an  extraosseous  compo-
nent. O’Donnell et al. [74] reported that the pres-
ence of pathologic fracture is associated with an 
increased incidence of recurrence. Balke et al. [2] 
believe that extraosseous component is prognostic 
of recurrence, giving a fourfold increase in the risk 
of relapse. In contrast, Errani et al. [69] found no 
statistically significant difference in recurrence rate 
and the presence of cortical destruction and a soft 
tissue component. Wang et al. [67] believe that the 
cortical destruction and size of the lesion can be 
objective factors to determine the type of surgical 
treatment. Klenke et al. [70] indicate that gender, 
localization, stage of the lesion, the presence of a 
soft tissue component and a pathological fracture 
are unrelated to the risk of recurrence. O’Donnell et 
al. [74] and Errani et al. [69] believe that lesions of 
the distal radius have a greater tendency to recur.
FOLLOW-UP
After surgery, patients with GCTB require long-term 
follow-up. Most commonly this tumor recurs within 
the first 12 to 36 months, rarely after five to six years 
[8,7,103]. About 70% of recurrences occur during 
the first 2 years after the operation [2,27,69,76,82]. 
In the literature there is evidence of recurrence ob-
served  after  20  and  even  42  years  after  surgery 
[104]. Errani et al. [69] and Niu et al. [71] suggest 
that patients with GCTB should be monitored until 
the tenth year after surgery. It is assumed that re-
lapses are due to activation of the remaining “dor-
mant” tumor cells [105]. Patients with GCTB should 
be  evaluated  for  local  recurrence  and  pulmonary 
metastases at 4-month intervals for the first 2 years 
and at 6-month intervals thereafter up to 5 years 
[7,8,103]. The first symptom of recurrence is pain. 
Follow-up of patients with GCTB is done with peri-
odic radiographs that are compared with the previ-
ous ones; this helps to differentiate recurrence from 
postoperative changes. Bone graft usually under-
goes bone remodeling. The combination of osteoly-
sis and cortical expansion is particularly important 
for differentiation between bone resorption and re-Georgiev G.P. et al. Giant cell tumor of bone 482
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currence [106]. The presence of a soft tissue recur-
rence may present on conventional radiographs as 
peripheral calcifications. In cases of recurrence, CT 
is used to evaluate bone changes and MRI - the 
eventual  soft  tissue  component.  When  PMMA  is 
used to pack the cavity, it is important to determine 
whether the defect has been initially filled complete-
ly during surgery, which could otherwise be wrongly 
interpreted as osteolysis and respectively a relapse 
[106]. PMMA is not resorbable and its high radio-
graphic density is in sharp contrast with the lower 
density of the adjacent bone. It should be noted that 
after curettage and packing with PMMA, an osteo-
lytic zone of about 2 mm around the cement has 
been  observed,  caused  by  the  thermal  damage 
of the surrounding bone. This radiolucent zone is 
surrounded by a thin outer sclerotic rind for about 
six months [107]. The presence of larger or longer-
lasting osteolysis or the absence of a sclerotic rind 
between the cement and the surrounding cancel-
lous bone suggests a recurrence [103,106]. In cas-
es of doubt it is appropriate to obtain a MRI where 
PMMA has low signal intensity in all sequences and 
is readily distinguishable from the existing relapse 
[97,106].
Chest radiographs and CT evaluate the pulmo-
nary metastases [25,26]. Although the prognosis of 
the metastases, with or without surgical removal, is 
usually good [25,26] there are reports of lethal out-
come due to metastasizing GCTB [99].
RADIOTHERAPY
Although surgery remains the method of first choice 
in the treatment of GCTB, in some cases with lo-
cations in the spine, sacrum or pelvis which hinder 
surgery  the  use  of  adjuvant  radiotherapy  is  ap-
propriate [8,90]. Radiotherapy is also warranted in 
inoperable cases [4]. Several cases of malignant 
GCTB after radiotherapy have been described. The 
use of modern technologies in the field and apply-
ing megavoltage radiotherapy techniques reduces 
the risk of malignant transformation and longer and 
better local control [108].
Molecular adjuvant therapy in the treatment 
of GCTB
In recent years a number of studies have demon-
strated that the receptor activator of nuclear fac-
tor kappa-B ligand (RANKL) plays a key role in the 
pathogenesis  of  GCTB.  Promising  results  have 
been  achieved  by  the  neoadjuvant  use  of  Deno-
sumab which inhibits RANKL [109-111]. This ther-
apy induces calcification of the affected soft tissues 
which allows the extension of the indication for cu-
rettage and additional adjuvants [79]. According to 
Branstetter et al. [112] the neoadjuvant use of De-
nosumab significantly reduced or eliminated RANK-
positive tumor giant cells. Denosumab also reduced 
the presence of proliferative, dense stromal cells, 
replacing them with non-proliferative, well differenti-
ated new bone.
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